Schizophrenia News and Research

Latest Schizophrenia News and Research

Seasonal light cycles can affect development of babies' specific brain function: Study

The season in which babies are born can have a dramatic and persistent effect on how their biological clocks function.

6 Dec 2010

Personal environment influences effects of genes and risk of disease

Personalized medicine centers on being able to predict the risk of disease or response to a drug based on a person's genetic makeup. But a study by scientists at Washington University School of Medicine in St. Louis suggests that, for most common diseases, genes alone only tell part of the story.

4 Dec 2010

Gene mutation can lead to different mental illnesses when influenced by same environmental factor

Male mice born with a genetic mutation that's believed to make humans more susceptible to schizophrenia develop behaviors that mimic other major psychiatric illnesses when their mothers are exposed to an assault to the immune system while pregnant, according to new Johns Hopkins research.

4 Dec 2010

AVMA condemns actions of animal rights activists against UCLA research neuroscientist

Citing its policy on the use of animals in research, testing and education, the American Veterinary Medical Association (AVMA) today condemned the recent actions of animal rights activists who have targeted a University of California research neuroscientist. The scientist's work includes the use of nonhuman primates to research biochemical factors that contribute to methamphetamine and tobacco addiction in adolescents, as well as to better understand cognitive problems that contribute to behavioral, speech and reasoning disabilities in schizophrenics.

2 Dec 2010

People with mental health diagnoses receives poor quality of preventive mass screening

Dr Alex Mitchell, of the Department of Cancer Studies and Molecular Medicine at the University of Leicester, led the study which has been published in the journal General Hospital Psychiatry. Dr Mitchell said preventive screening refers to population based medical tests such as mammography, colonoscopy, blood pressure testing or cholesterol levels to detect conditions such as cancer, diabetes or heart conditions. These screening programmes are typically administered widely in order to help with early detection or prevention and have been credited with improving outcomes of several key medical conditions.

2 Dec 2010

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.

30 Nov 2010

Nine out of ten of all primary care centers in Sweden prescribe physical activity

Prescribing physical activity for the purpose of preventing and treating various conditions can now become a reality for healthcare professionals all over the world.

30 Nov 2010

Study finds gender difference in brain function of schizophrenics

Schizophrenia is a mental disorder that differs between the sexes in terms of age at onset, symptomatology, response to medication, and structural brain abnormalities. Now, a new study from the Universit- de Montr-al shows that there is gender difference between men and women's mental ability with women performing better than men.

20 Nov 2010

Ontario Brain Institute initiates new venture to help people with neurological disorders

Ontario took a major step to help the one million people in the province with neurological disorders and the 2.6 million Ontarians who will be affected by a neurological condition in their lifetime.

20 Nov 2010

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources. It also can have devastating health-related and social effects on people with the disease, their families and caregivers.

20 Nov 2010

Scientists identify gene variants associated with eating disorder

Scientists at The Children's Hospital of Philadelphia have identified both common and rare gene variants associated with the eating disorder anorexia nervosa.

20 Nov 2010

Scientists solve receptor structure that responds to neurotransmitter dopamine

A team led by scientists at The Scripps Research Institute has solved the structure of one of the receptors that responds to the neurotransmitter dopamine. Although dopamine transmission is essential to normal brain functioning, the biological assembly of the molecules involved in this crucial neuronal interplay had not been known until now.

19 Nov 2010

Neural differences may help explain prevalence of mental disorders in boys

Many mental health disorders, such as autism and schizophrenia, produce changes in social behavior or interactions. The frequency and/or severity of these disorders is substantially greater in boys than girls, but the biological basis for this difference between the two sexes is unknown.

18 Nov 2010

Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine

Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the antidepressant efficacy of the NMDA receptor antagonist ketamine.

18 Nov 2010

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin two Phase I safety trials to test NSI-189, its first small molecule compound, for the treatment of major depression. NSI-189 is a proprietary new chemical entity discovered by Neuralstem that stimulates new neuron growth in the hippocampus, an area of the brain that is believed to be involved in depression.

18 Nov 2010

PrecisionMed enrolls first subject in Multiple Sclerosis Registry

PrecisionMed Inc. today announced at the Society for Neuroscience annual meeting in San Diego, enrollment of the first subject into the PrecisionMed Multiple Sclerosis (MS) Registry. The PrecisionMed MS Registry is a biological sample bank of DNA and serial RNA, CSF, serum and plasma associated with serial clinical testing utilizing PrecisionMed's clinical data procurement and storage capabilities.

17 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

Researchers develop human cell-based model of Rett syndrome

A groundbreaking study published Friday in the leading scientific journal, Cell, revealed that a team of investigators had successfully generated nerve cells using skin cells from four individuals with Rett syndrome. The study, funded in part by IRSF, was led by Dr. Alysson Muotri at the University of California, San Diego--a leading researcher in the stem cell field.

16 Nov 2010

Researchers find additional work of oxytocin hormone

New human research suggests the chemical oxytocin dubbed the "cuddle hormone" because of its importance in bonding between romantic partners and mothers and children also influences feelings of well-being and sensitivity to advertising.

15 Nov 2010

No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia

The potential for harmful side effects associated with anti-psychotic medications for treating schizophrenia is a frustration for mental-health professionals who must balance this with the positive benefits of drugs. For example, the issue of the antipsychotic drug ziprasidone lengthening the QTc interval, a possible indicator of life-threatening heart arrhythmias, has demanded much attention among clinicians since the drug was introduced in 2001.

15 Nov 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

Seasonal light cycles can affect development of babies' specific brain function: Study

Personal environment influences effects of genes and risk of disease

Gene mutation can lead to different mental illnesses when influenced by same environmental factor

AVMA condemns actions of animal rights activists against UCLA research neuroscientist

People with mental health diagnoses receives poor quality of preventive mass screening

Cyrenaic announces results of CYR-101 Phase IIa clinical trial for schizophrenia

Nine out of ten of all primary care centers in Sweden prescribe physical activity

Study finds gender difference in brain function of schizophrenics

Ontario Brain Institute initiates new venture to help people with neurological disorders

Psychiatric hospitalization rate decreases among adults with schizophrenia treated with INVEGA SUSTENNA: Study

Scientists identify gene variants associated with eating disorder

Scientists solve receptor structure that responds to neurotransmitter dopamine

Neural differences may help explain prevalence of mental disorders in boys

Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine

Neuralstem files NSI-189 IND with FDA for Phase I safety trials for major depression

PrecisionMed enrolls first subject in Multiple Sclerosis Registry

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Researchers develop human cell-based model of Rett syndrome

Researchers find additional work of oxytocin hormone

No difference in risk of nonsuicide death between ziprasidone and olanzapine for schizophrenia

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Schizophrenia News and Research

Latest Schizophrenia News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in